EGFR and breast cancer: GRh2 liposomes (LTL@Rh2@Lipo-GE11), which target EGFR, were able to counteract breast cancer cells with high EGFR hyperexpression more accurately, showed high specificity and strong cytotoxicity, inhibited the growth and migration of breast cancer cells, and are a promising therapeutic option (29).